Robert Gut Sells 7,552 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 7,552 shares of uniQure stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $26.05, for a total transaction of $196,729.60. Following the sale, the director owned 27,435 shares in the company, valued at approximately $714,681.75. The trade was a 21.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Thursday, June 11th, Robert Gut sold 2,726 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total transaction of $73,765.56.

uniQure Stock Performance

QURE opened at $27.57 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a fifty day moving average of $22.52 and a 200 day moving average of $21.80. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, sell-side analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analyst Weigh In

A number of analysts have issued reports on QURE shares. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. HC Wainwright cut their target price on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $42.83.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. State Street Corp boosted its holdings in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. increased its position in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. Orbimed Advisors LLC lifted its position in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new stake in uniQure in the fourth quarter worth $33,062,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.